MCL Literature Feed

Italian real-world data highlights the poor prognosis and significant unmet clinical needs for relapsed/refractory MCL patients following covalent BTKi failure, emphasizing the urgency for novel treatment strategies.

This dual-center retrospective analysis of 20 patients with blastoid MCL characterizes its clinical features and prognosis, adding to the limited evidence base for this aggressive subtype.

This retrospective study outlines real-world treatment patterns for MCL from a single private practice in Brazil, providing crucial data on management outside of traditional clinical trial or academic settings.

This retrospective review of 14 Moroccan patients describes real-world MCL clinical features and treatment patterns, providing rare epidemiological data from North Africa.

This Mendelian randomization study suggests potential causal links between socioeconomic factors and lymphoma development, which may help define modifiable risk factors relevant to MCL etiology.

In a large retrospective series of bilateral lacrimal gland lesions, mantle cell lymphoma was identified as a rare cause (4.4%), highlighting an uncommon extranodal presentation for clinicians.

This single-center retrospective study characterizes the aggressive clinical and pathological features of blastoid MCL, underscoring its diagnostic challenges and the need for novel therapeutic approaches for this high-risk subtype.

This study shows ROR1 is heterogeneously expressed in 44% of MCL tumors, indicating that patient selection will be critical for developing ROR1-targeted therapies like ADCs or CAR-T.

A novel 7-gene signature linked to ferroptosis predicts overall survival in MCL, identifying high-risk patients and suggesting potential new therapeutic targets like the MEK inhibitor Trametinib.

In a real-world cohort including MCL, the Hematotox-Score predicted early cytopenias post-CAR-T but not survival, underscoring the need for improved prognostic tools for toxicity management.